Phase II study with temozolomide and capecitabine for patients with refractory colorectal cancer

Trial Profile

Phase II study with temozolomide and capecitabine for patients with refractory colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Capecitabine (Primary) ; Temozolomide (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TEM
  • Most Recent Events

    • 18 Oct 2016 New trial record
    • 11 Oct 2016 Results (n=40) presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top